Literature DB >> 6252294

Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG.

K V Toyka, B Löwenadler, K Heininger, U A Besinger, K L Birnberger, A Fateh-Moghadam, E Heilbronn.   

Abstract

Using the mouse passive transfer model, the effects of purified human myasthenic immunoglobulin G and of the monovalent Fab fragment on neuromuscular junctions were investigated. Treatment with IgG markedly reduced amplitudes of miniature endplate potentials. When Fab fragments were transferred alone or with subsequent addition of IgG no neuromuscular transmission block was induced. Myasthentic IgG and Fab were specifically demonstrated at the neuromuscular junctions by immunohistochemistry. On electronmicroscopy endplate structure was normal in transfer experiments using IgG for up to 30 days. It is suggested that Fab fragments bind to acetylcholine receptors without affecting transmission and protect them from the attack of complete IgG antibodies.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6252294      PMCID: PMC490676          DOI: 10.1136/jnnp.43.9.836

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  24 in total

1.  Experimental myasthenia in rabbits: biochemical, immunological, electrophysiological, and morphological aspects.

Authors:  E Heilbronn; C Mattsson; L E Thornell; M Sjöström; E Stålberg; P Hilton-Brown; D Elmqvist
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

2.  An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis.

Authors:  E X Albuquerque; J E Rash; R F Mayer; J R Satterfield
Journal:  Exp Neurol       Date:  1976-06       Impact factor: 5.330

3.  Serum disappearance and catabolism of homologous immunoglobulin fragments in rats.

Authors:  W P Arend; F J Silverblatt
Journal:  Clin Exp Immunol       Date:  1975-12       Impact factor: 4.330

Review 4.  The complement system of man. I.

Authors:  S Ruddy; I Gigli; K F Austen
Journal:  N Engl J Med       Date:  1972-09-07       Impact factor: 91.245

5.  Myasthenia gravis: passive transfer from man to mouse.

Authors:  K V Toyka; D B Brachman; A Pestronk; I Kao
Journal:  Science       Date:  1975-10-24       Impact factor: 47.728

6.  Localization of acetylcholine receptor by 125I-labeled alpha-bungarotoxin binding at mouse motor endplates.

Authors:  H C Fertuck; M M Salpeter
Journal:  Proc Natl Acad Sci U S A       Date:  1974-04       Impact factor: 11.205

7.  Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.

Authors:  K V Toyka; D B Drachman; D E Griffin; A Pestronk; J A Winkelstein; K H Fishbeck; I Kao
Journal:  N Engl J Med       Date:  1977-01-20       Impact factor: 91.245

8.  Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome.

Authors:  A G Engel; T Santa
Journal:  Ann N Y Acad Sci       Date:  1971-09-15       Impact factor: 5.691

9.  End-plate potentials in experimental autoimmune myasthenia gravis in rats.

Authors:  E H Lambert; J M Lindstrom; V A Lennon
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

10.  The ultrastructural basis of capillary permeability studied with peroxidase as a tracer.

Authors:  M J Karnovsky
Journal:  J Cell Biol       Date:  1967-10       Impact factor: 10.539

View more
  9 in total

Review 1.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

Review 2.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 3.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

4.  Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

Authors:  Linda L Kusner; Mario Losen; Angela Vincent; Jon Lindstrom; Socrates Tzartos; Konstantinos Lazaridis; Pilar Martinez-Martinez
Journal:  Exp Neurol       Date:  2015-03-03       Impact factor: 5.330

5.  Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. I. Receptor degradation.

Authors:  S Wilson; A Vincent; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-05       Impact factor: 10.154

6.  Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor.

Authors:  J Bufler; S Kahlert; S Tzartos; K V Toyka; A Maelicke; C Franke
Journal:  J Physiol       Date:  1996-04-01       Impact factor: 5.182

7.  Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.

Authors:  Mario Losen; Aran F Labrijn; Vivianne H van Kranen-Mastenbroek; Maarten L Janmaat; Krista G Haanstra; Frank J Beurskens; Tom Vink; Margreet Jonker; Bert A 't Hart; Marina Mané-Damas; Peter C Molenaar; Pilar Martinez-Martinez; Eline van der Esch; Janine Schuurman; Marc H de Baets; Paul W H I Parren
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

8.  Glycine receptor autoantibodies disrupt inhibitory neurotransmission.

Authors:  Sarah J Crisp; Christine L Dixon; Leslie Jacobson; Elodie Chabrol; Sarosh R Irani; M Isabel Leite; Guy Leschziner; Sean J Slaght; Angela Vincent; Dimitri M Kullmann
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

Review 9.  Autoimmune synaptopathies.

Authors:  Sarah J Crisp; Dimitri M Kullmann; Angela Vincent
Journal:  Nat Rev Neurosci       Date:  2016-02       Impact factor: 34.870

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.